CFO
ONC icon

Callan Family Office’s BeOne Medicines Ltd ONC Stock Holding History

Callan Family Office’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$499K Sell
1,752
-671
-28% -$198K 0.01% 812
2026
Q1 		$720K Sell
2,423
-251
-9% -$81.2K 0.02% 651
2025
Q4 		$812K Buy
2,674
+1,743
+187% +$571K 0.02% 610
2025
Q3 		$317K Sell
931
-94
-9% -$28.5K 0.01% 691
2025
Q2 		$248K Buy
+1,025
New +$251K 0.01% 831

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Callan Family Office's ONC Position: Q2 2026 in Review

Callan Family Office reduced its BeOne Medicines Ltd (ONC) stake by 28% in Q2 2026, selling an estimated $198K and leaving 1,752 shares worth $499K. The position accounts for 0.01% of the portfolio, ranked #812.

Callan Family Office first reported a position in ONC in Q2 2025 and has held it in 5 quarters since. The position peaked at $812K in Q4 2025. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Callan Family Office held 1,752 shares of BeOne Medicines Ltd worth $499K as of Q2 2026.
  • Callan Family Office sold 671 BeOne Medicines Ltd shares in Q2 2026, an estimated $198K.
  • BeOne Medicines Ltd made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #812 holding.
  • Callan Family Office first reported a position in BeOne Medicines Ltd in Q2 2025 and has held it in 5 quarters since.
  • Callan Family Office's BeOne Medicines Ltd position peaked at $812K in Q4 2025.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.